Publicação
Sugammadex : implicações farmacoeconómicas e consequências na prática clínica anestésica presente e futura
| Resumo: | Sugammadex, a modified gamma-cyclodextrine, belongs to a new class of drugs used in anesthesia.It was first approved in the European Union, and it is now available for clinical use in over 50 countries over the world, since 2008.It is used to rapidly and efficiently reverse neuromuscular blockade induced by the aminosteroidneuromuscular blocking drugs, and is also secure and predictable in reverse of the profound blockade.This type of drug has been shown to be efficacious and has had a good safety profile in the number of patients exposed to the drug so far, studied in many clinic trials.The introduction of Sugammadex into clinical practice has increased the options in treating patients across a wide range of clinical situations, giving a so far never achieved reliable and control grade, to the anesthetists. There are currently important pharmaco-economic barriers to the widespread introduction of this drug, due to its recent use in clinical practice, expensive costs and a paucity of evidence-based studies relied on its still uncertain cost-effectiveness and cost-benefit aspects. Despite of all,and due to its global characteristics, it is expected Sugammadex come to offer unique benefits in BNM reversal, with potential to transform the paradigms in the present and future anesthetic practice. |
|---|---|
| Autores principais: | Ramos, Paulo Brites |
| Assunto: | Agentes bloqueadores neuromusculares Bloqueio neuromuscular residual Sugammadex Fármaco-economia Custo-efetividade Custo-benefício |
| Ano: | 2014 |
| País: | Portugal |
| Tipo de documento: | dissertação de mestrado |
| Tipo de acesso: | acesso restrito |
| Instituição associada: | Universidade de Lisboa |
| Idioma: | português |
| Origem: | Repositório da Universidade de Lisboa |
| Resumo: | Sugammadex, a modified gamma-cyclodextrine, belongs to a new class of drugs used in anesthesia.It was first approved in the European Union, and it is now available for clinical use in over 50 countries over the world, since 2008.It is used to rapidly and efficiently reverse neuromuscular blockade induced by the aminosteroidneuromuscular blocking drugs, and is also secure and predictable in reverse of the profound blockade.This type of drug has been shown to be efficacious and has had a good safety profile in the number of patients exposed to the drug so far, studied in many clinic trials.The introduction of Sugammadex into clinical practice has increased the options in treating patients across a wide range of clinical situations, giving a so far never achieved reliable and control grade, to the anesthetists. There are currently important pharmaco-economic barriers to the widespread introduction of this drug, due to its recent use in clinical practice, expensive costs and a paucity of evidence-based studies relied on its still uncertain cost-effectiveness and cost-benefit aspects. Despite of all,and due to its global characteristics, it is expected Sugammadex come to offer unique benefits in BNM reversal, with potential to transform the paradigms in the present and future anesthetic practice. |
|---|